Citing the lack of enough events to validate the primary endpoint, AbbVie (NYSE:ABBV) stops the Phase 3 SONAR study assessing atrasentan in patients type 2 diabetes and stage 2 - 4 chronic kidney disease.
Atrasentan (ABT-627) is an endothelin A antagonist. Endothelins are peptides that constrict blood vessels and raise blood pressure.
Previously: AbbVie (ABBV -1%) says it's initiated a Phase 3 clinical study of diabetic nephropathy with... (May 20, 2013)
Subscribe for full text news in your inbox